Document is current
Any future updates will be listed below
-
Authors
Giesel, Frederik L.
Koerber, Stefan A.
Hadaschik, Boris
Kiefer, Selina
Schwarzenboeck, Sarah
Rahbar, Kambiz
Derlin, Thorsten
Grott, Christoph A.
Heck, Matthias
Jilg, Cordula
Meyer, Philipp T.
Ruf, Juri
Schmidt, Karl
Kotzerke, Joerg
la Fougère, Christian
Reischl, Gerald
Virgolini, Irene
Herrmann, Ken
Burger, Irene A.
Lorenzini, Theo
Werner, Martin
Stenzinger, Albrecht
Schwamborn, Kristina
Radtke, Jan Philipp
Hohenfellner, Markus
Debus, Juergen
Weber, Wolfgang A.
Haberkorn, Uwe
Kopka, Klaus
Eiber, Matthias https://orcid.org/0000-0003-2130-644X
,
Sahm, Ursula
Rausch, Steffen
Decristofero, Clemens
Uprimny, Christian
di Santo, Gianpaolo
Rangger, Christine
Wunderlich, Gerd
Huber, Johannes
Sommer, Ulrich
Johayem, Anass
Kaufmann, Philipp A.
Eberli, Daniel
Tonndorf-Martini, Eric
Muehlhauser, Mathias
Kratochwil, Clemens
Schubert, Kai
Kiss, Oliver
Hennrich, Ute
Choyke, Peter
Zippel, Claus
Wiestler, Otmar
Baumann, Michael
Reil-Held, Annette
Meyer, Volker
Meese, Sandra
Maurer, Tobias
Remke, Marianne
Watzlowik, Petra
Gildehaus, Franz
Prante, Olaf
Höpping, Alexander
Kabuss, Gesine
Gschwend, Jürgen
Kienzle, Gabriele
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 18 August 2025
First Online: 15 November 2025
Declarations
:
: Approved by the IRB at the main site in Heidelberg, following subsequent approval at all participating sites.
: All patients have been consented for the trial.
: Permission to published was included in the ICF and granted by DKTK.
: EudraCT-Nr. 2016–001815-19,ClinicalTrials.gov ID NCT03362359.DRKS ID DRKS00013701.
: KK is a co-inventor of PSMA-617 and PSMA-1007 and is/was a member of the scientific advisory board of Telix and Fuzionaire Tx. TD reports personal fees from ABX-CRO and Novartis Radiopharmaceuticals. KH reports personal fees from Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, ymabs, institutional grants from Novartis and Sophie Biosciences, honoraria from PeerVoice, support for travel from Janssen, stock/stock options from Sofie Biosciences, Pharma15, NVision, Convergent, Aktis Oncology, AdvanCell. JC reports stocks from Telix radiopharmaceuticals and Fuzionaire Theranostics. SK reports research grants from Vieway, honoraria from IBA Dosimetry, Think Wired!, PET e.v., Streamed up. SS reports honoraria from ABX-CRO, Oncobeta and AstraZeneca, grants from Novartis. AS honoraria from Agilent, Aignostics, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda, Thermo Fisher and grants from Bayer, BMS, Chugai, Incyte, MSD. WAW is an associate editor of EJNMMI. He has received research support from BED, ITM, Novartis, Pentixapharm, Ratio Therapeutics, and Rayzebio. He serves on advisory boards for Curium, ITM, Novartis, Ornano Med, Ratio Therapeutics, Imuveo. BH reports grants from Novartis, BMS, royalties from Uromed, honoraria from Janssen, Bayer, Novartis, BMS, ABX, Merck, Onkowissen, Accord Healthcare, AstraZeneca, MSD, Pfizer, Amgen, Astellas, Lightpoint medical, Point Biopharma, Ipsen, Telix. ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA®. ME serves on advisory boards and/or steering comittes for Novartis, Blue Earth Diagnostics and Telix. FLG reports being an inventor of FAP-ligands (FAPI-46 and FAPI-74), PSMA-1007, and PSMA-GCK01, as well as an advisor at ABX GmbH, Telix Pharmaceuticals Ltd., SOFIE Biosciences, Alfafusion, and Rhine Pharma.
